Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNB-001
- Development stage
- Phase 3
- Lead developer
- PNB Vesper Life Sciences
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PNB-001 is a novel small molecule drug developed by PNB Vesper Life Sciences. It acts as a dual cholecystokinin (CCK) receptor ligand—specifically as a CCK-A (cholecystokinin A) receptor agonist and CCK-B (cholecystokinin B/gastrin) receptor antagonist. This unique mechanism underlies its anti-inflammatory, analgesic, and immune-modulating properties. Preclinical studies have shown efficacy in models of inflammatory bowel disease (IBD), pain, and inflammation. Clinically, it has been evaluated for COVID-19 infection as an immune modulator in moderate cases and has demonstrated safety in Phase I trials with mild adverse events at high doses. The drug is orally administered and has also been explored for potential use in inflammatory pain conditions and small cell lung cancer[1][2][3][4][5].
- Brand names
- GPP-BalacovinGPP-Baladol
- Other names
- PNB 001PNB001PNB-001
02
Targets
CCKAR (Cholecystokinin A receptor)CCK2R (Cholecystokinin 2 Receptor)
Beyond the preview
Go deeper on PNB-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNB-001.